[HTML][HTML] Elamipretide for Barth syndrome cardiomyopathy: Gradual rebuilding of a failed power grid

HN Sabbah - Heart failure reviews, 2022 - Springer
Barth syndrome is a rare and potentially fatal X-linked disease characterized by
cardiomyopathy, skeletal muscle weakness, growth delays, and cyclic neutropenia. Patients …

[HTML][HTML] Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide

HN Sabbah - Heart failure reviews, 2021 - Springer
Barth syndrome (BTHS) is a rare, X-linked recessive, infantile-onset debilitating disorder
characterized by early-onset cardiomyopathy, skeletal muscle myopathy, growth delay, and …

Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets

HM Zegallai, GM Hatch - Molecular and cellular biochemistry, 2021 - Springer
Barth syndrome is a rare X-linked genetic disease classically characterized by
cardiomyopathy, skeletal myopathy, growth retardation, neutropenia, and 3 …

Current and future treatment approaches for Barth syndrome

R Thompson, J Jefferies, S Wang… - Journal of Inherited …, 2022 - Wiley Online Library
Barth Syndrome is an X‐linked disorder of mitochondrial cardiolipin metabolism caused by
pathogenic variants in TAFAZZIN with pleiotropic effects including cardiomyopathy …

A critical appraisal of the tafazzin knockdown mouse model of Barth syndrome: what have we learned about pathogenesis and potential treatments?

M Ren, PC Miller, M Schlame… - American Journal of …, 2019 - journals.physiology.org
Pediatric heart failure remains poorly understood, distinct in many aspects from adult heart
failure. Limited data point to roles of altered mitochondrial functioning and, in particular …

[HTML][HTML] Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome

B Hornby, WR Thompson, M Almuqbil… - Orphanet journal of rare …, 2022 - Springer
Background Natural history studies are increasingly recognized as having an important role
in drug development for rare diseases. A phase 3, observational, retrospective, and non …

Cardiomyopathy, mitochondria and Barth syndrome: iPSCs reveal a connection

KK Raval, TJ Kamp - Nature medicine, 2014 - nature.com
Barth syndrome is a rare X-linked genetic disorder caused by mutations in the tafazzin (TAZ)
gene that result in dilated cardiomyopathy, skeletal myopathy and neutropenia. Tafazzin has …

[HTML][HTML] A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder …

WR Thompson, B Hornby, R Manuel, E Bradley… - Genetics in …, 2021 - Elsevier
Purpose To evaluate effectiveness of elamipretide in Barth syndrome (BTHS), a genetic
condition of defects in TAZ, which causes abnormal cardiolipin on the inner mitochondrial …

[HTML][HTML] Treatment of Barth syndrome by cardiolipin manipulation (CARDIOMAN) with bezafibrate: Protocol for a randomized placebo-controlled pilot trial conducted in …

L Dabner, GE Pieles, CG Steward… - JMIR Research …, 2021 - researchprotocols.org
Background: Barth syndrome is a rare, life-threatening, X-linked recessive genetic disease
that predominantly affects young males and is caused by abnormal mitochondrial lipid …

Metabolomic biomarkers from patients with Barth syndrome treated with elamipretide: insights from the TAZPOWER study

PJ Oates, DA Brown, HJ Vernon, JA Gangoiti… - MedRxiv, 2020 - medrxiv.org
Background Barth syndrome is an inherited disorder that results from pathogenic mutations
in TAZ, the gene responsible for encoding tafazzin, an enzyme that remodels the …